companiesCompany
Sino Biopharmaceutical (Chia Tai Tianqing)
aka Sino Biopharm, 中国生物制药, Chia Tai Tianqing, CTTQ
Sino Biopharm, through Chia Tai Tianqing, sells anlotinib, one of China's biggest cancer drugs, and acquired LaNova Medicines to add bispecific antibodies and ADCs.
Overview
Anlotinib (Focus V) approved 2018 across lung cancer, sarcoma and thyroid cancer; the PD-L1 antibody benmelstobart (TQB2450) approved 2024 for small cell lung cancer with anlotinib; a large hepatitis and oncology generics franchise. In 2025 it agreed to acquire LaNova Medicines, whose PD-1 x VEGF bispecific LM-299 had been licensed to Merck & Co. in 2024, for up to about $951 million, an example of Chinese pharma buying Chinese biotech.
Headquarters
Hong Kong / Nanjing, CN
Scorecard
All companies#56of 680 companies, score 45
- approved products +6
- targets +6
- modalities +2
- regions +1
- registry trials +30
1 approved, 0 in phase 3, 0 earlier, 3 targets, 408 registry studies. Formula on the scorecards page.
Deals
Deal map| Date | Deal | Type | Upfront | Total | Source |
|---|---|---|---|---|---|
| 2025-07 | LaNova Medicines to Sino Biopharmaceutical (Chia Tai Tianqing) LaNova Medicines (remaining equity), developer of LM-299 (PD-1 x VEGF, licensed to Merck & Co.) and ADCs | Acquisition | not disclosed | up to about $951m | source |
Type
pharma · 1177.HK
Stage
Public
Website
Pages like this
not linked directly; found by shared links- PersonYing Cheng
Shares Anlotinib and the tag china.
- CompanyHansoh Pharmaceutical Group
Shares Merck & Co. (MSD) and the tag china.